Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.41 |
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10976269 | 0.76 | IDO1 (0.41) | EPHX1IDO1NOS3NOS1NOS2 | |
| SCHEMBL17251292 | 0.76 | L3MBTL1 (0.42) | EPHX1ATML3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL7359781 | 0.76 | EPHX1 (0.44) | EPHX1IDO1NOS3NOS1NOS2 | |
| SCHEMBL2171639 | 0.76 | TSHR (0.42) | EPHX1IDO1NOS3NOS1NOS2 | |
| SCHEMBL1615641 | 0.76 | EPHX1 (0.40) | EPHX1IDO1NOS3NOS1NOS2 | |
| SCHEMBL10566452 | 0.76 | EPHX1 (0.47) | EPHX1ATML3MBTL1CYP2C19POLB | |
| SCHEMBL9457041 | 0.72 | SLC6A4 (0.42) | EPHX1SLC6A4SLC6A3 | |
| SCHEMBL11234251 | 0.71 | IDO1 (0.41) | IDO1NOS3NOS1NOS2CYP1A2 | |
| SCHEMBL10899765 | 0.71 | L3MBTL1 (0.47) | ATML3MBTL1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3922984 | 0.71 | IDO1 (0.41) | EPHX1IDO1NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3412663-B1 | NITROGEN-CONTAINING HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2022-09-07 | — | — | EP | disclosed |
| US-20220235047-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE | SHIONOGI & CO., LTD. (JP) | 2022-07-28 | — | — | US | disclosed |
| EP-4028130-A1 | BENZYL AMINE-CONTAINING 5,6-HETEROAROMATIC COMPOUNDS USEFUL AGAINST MYCOBACTERIAL INFECTION | Shionogi & Co., Ltd (JP) | 2022-07-20 | — | — | EP | disclosed |
| WO-2022119899-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME BC1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN | SHIONOGI & CO., LTD. (JP) | 2022-06-09 | — | — | WO | disclosed |
| EP-3976031-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME BC1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE | Shionogi & Co., Ltd (JP) | 2022-04-06 | — | — | EP | disclosed |
| EP-3330256-B1 | HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY | SHIONOGI & CO (JP) | 2021-06-16 | — | — | EP | disclosed |
| US-11008320-B2 | Nitrogen-containing heterocycle and carbocycle derivatives having TrkA inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2021-05-18 | — | — | US | disclosed |
| WO-2021050708-A1 | BENZYL AMINE-CONTAINING 5,6-HETEROAROMATIC COMPOUNDS USEFUL AGAINST MYCOBACTERIAL INFECTION | SHIONOGI & CO., LTD. (JP) | 2021-03-18 | — | — | WO | disclosed |
| EP-2772480-B2 | HIV REPLICATION INHIBITOR | SHIONOGI & CO (JP) | 2020-12-09 | — | — | EP | disclosed |
| WO-2020243224-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE | SHIONOGI & CO., LTD. (JP) | 2020-12-03 | — | — | WO | disclosed |
| US-9199959-B2 | HIV replication inhibitor | SHIONOGI & CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20150266865-A1 | DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
| EP-2912035-A1 | DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | Shionogi & Co., Ltd. (JP) | 2015-09-02 | — | — | EP | disclosed |
| US-20140275074-A1 | HETEROCYCLIC DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-09-18 | — | — | US | disclosed |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2014-09-04 | — | — | US | disclosed |
| EP-2772480-A1 | HIV REPLICATION INHIBITOR | Shionogi & Co., Ltd. (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2752410-A1 | HETEROCYCLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | Shionogi & Co., Ltd. (JP) | 2014-07-09 | — | — | EP | disclosed |
| WO-2014065434-A1 | DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-05-01 | — | — | WO | disclosed |
| WO-2007001406-A2 | ARYL-CONTAINING MACROCYCLIC COMPOUNDS | CHIRON CORPORATION (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275074-A1 | HETEROCYCLIC DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | PTGDR, PTGDR2, PTGER4 | EPHX1 700/4885IDO1 1633/4885NOS3 1201/4885 |
| US-20220235047-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE | CYC1, MT-CO1, ABCB11 | EPHX1 3129/4885IDO1 847/4885NOS3 921/4885 |
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | ACSS2, ACACB, ACAT2 | EPHX1 2865/4885IDO1 1356/4885NOS3 719/4885 |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SSU72, RTF2, ZC3HAV1 | EPHX1 4197/4885IDO1 1035/4885NOS3 1868/4885 |
| US-20150266865-A1 | DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, APP, BACE2 | EPHX1 1757/4885IDO1 2196/4885NOS3 2333/4885 |
| US-11008320-B2 | Nitrogen-containing heterocycle and carbocycle derivatives having TrkA inhibitory activity | NTRK2, NTRK3, NTRK1 | EPHX1 3211/4885IDO1 1419/4885NOS3 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.